Companion Animal Postoperative Pain Management Therapeutics Market
Report ID: SQMIG35I2739
Report ID: SQMIG35I2739
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I2739 |
Region:
Global |
Published Date: June, 2026
Pages:
157
|Tables:
120
|Figures:
77
Global Companion Animal Postoperative Pain Management Therapeutics Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 731.84 Million in 2025 to USD 1285.4 Million by 2033, growing at a CAGR of 7.23% during the forecast period (2026-2033).
The primary driver of the companion animal postoperative pain management therapeutics market is a confluence of rising pet ownership, higher standards of veterinary care, and pharmaceutical innovation. Analgesics, local anaesthetics, anti-inflammatories and multimodal protocols are part of this market; they are used post-surgery to help the patient recover faster and with less pain. Better pain control translates into better clinical outcomes, better relationships between the owner and the veterinarian, and differentiating the practice of veterinarians while increasing market demand. Development over the last ten years has seen a shift away from relying on traditional opioid and NSAID’s to more targeted molecules, long-acting injectable and implantable formulations, and examples include the injectable formulations of liposomal bupivacaine and meloxicam.
Building on therapeutic evolution, the key trend driving the global companion animal postoperative pain management therapeutics sector is accelerating clinical adoption driven by pet owner expectations and elective surgical volumes, which create persistent demand for improved analgesia. In response to the demand for human grade recovery from spay surgeries, orthopedic reconstructions and oncologic procedures, veterinarians have started using long-acting injectable medications as well as multimodal pain management approaches, resulting in fewer visits and fewer post-surgical complications. Pharmaceutical companies are investing in sustained release platforms and expanding labels therefore allowing for more annual product launches and clinician training programs. In developing markets, low baseline analgesic standards provide opportunities for uptake and bundled perioperative care packages allow for innovative solutions to be translated into increased revenue per case and ultimately scalable worldwide expansion.
How is AI Improving Clinical Trial Design in the Companion Animal Postoperative Pain Therapeutics Market?
AI is improving clinical trial design in the companion animal postoperative pain therapeutics market by enabling smarter patient selection, adaptive protocols and clearer endpoints. Key aspects are data driven phenotyping, predictive biomarkers and remote activity monitoring which reduce variability and strengthen signal detection. Today sponsors and veterinary researchers apply machine learning to combine clinical records, wearable data and owner reported outcomes to tailor inclusion criteria and dosing. This matters because the market is shifting toward biologics and long acting therapies where trial efficiency and humane endpoints are priorities. Examples include AI informed protocol optimization and patient to trial matching that speed development and enhance welfare.
In June 2025, Absci reported a partnership with Invetx to apply generative AI to antibody design for animal health. This innovation helps trial design by generating better candidate molecules, suggesting biomarkers and prioritizing study arms which supports faster, more efficient development and broader market adoption.
Market snapshot - (2026-2033)
Global Market Size
USD 682.5 Million
Largest Segment
Fastest Growth
Local Anesthetics
Growth Rate
7.23% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global companion animal postoperative pain management therapeutics market is segmented by drug class, animal, surgery type, end-user and region. Based on drug class, the market is segmented into NSAIDs (carprofen, meloxicam), opioids (tramadol, butorphanol), local anesthetics, alpha-2 agonists and others. Based on animal, the market is segmented into dogs and cats. Based on surgery type, the market is segmented into orthopedic surgery, soft tissue surgery and dental surgery. Based on end-user, the market is segmented into veterinary hospitals, veterinary clinics and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global companion animal postoperative pain management therapeutics market growth, Local anesthetics segment dominates because focused nerve blocks and infiltration techniques provide immediate, high efficacy pain relief that reduces reliance on systemic agents and shortens recovery times. Their versatility across procedures, compatibility with multimodal protocols, and growing clinician proficiency drive preference for local approaches, improving perioperative hemodynamic stability and owner perceived outcomes, which encourages broader adoption by practices seeking predictable analgesia and reduced adverse events and streamlined dosing workflows.
However, NSAIDs (meloxicam) are the most rapidly expanding area owing to oral convenience, long acting postoperative efficacy, and strong veterinarian and owner acceptance, which fosters routine prescribing and formulary placement, while ongoing formulation improvements and regulatory clarity accelerate uptake and open avenues for broader outpatient pain management products.
Orthopedic surgery segment leads because high intensity nociceptive input from bone and joint procedures necessitates robust multimodal analgesia, prompting routine use of long acting NSAIDs, opioids, nerve blocks, and adjunctive agents to control severe perioperative and recovery pain. The pain profile and demand for early mobilization are creating a push to create protocols, develop specialized training and education for clinicians, and invest in new technology and therapeutics that improve function and decrease risk of complications.
However, dental surgery is witnessing the strongest growth momentum as rising routine oral procedures and greater owner focus on dental health increase analgesic demand, encouraging targeted analgesics and local techniques. Innovation in short acting formulations, minimally invasive dental protocols, and better pain assessment tools accelerate outpatient treatment adoption and create new product and service opportunities.
To get detailed segments analysis, Request a Free Sample Report
As per the global companion animal postoperative pain management therapeutics market share, North America dominates due to a concentration of advanced veterinary infrastructure, integrated pharmaceutical and biotech presence, and high clinical awareness of postoperative pain management in companion animals. The ability to quickly take the newest discoveries in pain relief and ways to provide that pain relief to patients is made possible because of the partnerships that have been built by collaborating with academic institutions, specialty clinics, and those who manufacture healthcare products. Established methods for distributing products and educating professionals on how to use them will help ensure widespread adoption of the evidence-based clinical approaches to pain management. Owner commitment to providing a higher-level quality of care will stimulate demand for veterinary services. Investment in specialized pain clinics and wider uptake of multimodal analgesia have diversified treatment options, while focused post approval practitioner education and manufacturer prioritization of the region sustain rapid adoption and continuous refinement of clinical protocols.
Companion animal postoperative pain management therapeutics market in United States is driven by a dense network of specialty veterinary hospitals and academic research centers that shape clinical practice. Collaboration between industry and practitioners expedites introduction of innovative analgesics and delivery technologies. Distribution channels established and educational programs promote adherence to established guidelines while the owner's expectations and access to quality veterinary services have contributed to increased acceptance and integration of advanced postoperative pain control into clinical practice across all practice settings.
Companion animal postoperative pain management therapeutics market in Canada reflects a well established veterinary services framework with growing emphasis on evidence based analgesic protocols and practitioner training. Regions and veterinarians work together, along with colleges, to develop new methods of delivery and multiple ways to manage pain. Distributors and manufacturers are involved with targeted marketing to improve the availability of advanced therapeutic solutions through practitioner emphasis on the quality of recovery and communication with clients.
Europe is experiencing rapid expansion driven by converging forces of regulatory harmonization, rising clinical standards, and active engagement of veterinary associations that promote evidence based postoperative care. Established pharmaceutical and medtech firms are adapting global innovations to regional needs while regional research centers and specialty clinics validate efficacy and safety through collaborative studies and practitioner networks. Cross border distribution infrastructure and targeted educational initiatives facilitate dissemination of multimodal pain management protocols. Market growth is further stimulated by increasing owner awareness of animal welfare, greater willingness to invest in high quality postoperative care, and strategic product launches by manufacturers seeking to capture diverse national markets. These dynamics create a fertile environment for sustained product adoption and clinical refinement across Europe. Stakeholder collaboration remains pivotal to progress.
Companion animal postoperative pain management therapeutics market in Germany is anchored by a robust pharmaceutical and veterinary research ecosystem that supports clinical validation and product development. Advanced analgesic therapies and integrated perioperative plans are being implemented via institutional networks and top veterinary hospitals. Regulatory and professional frameworks stress the use of evidence; commercial pathways and focused education programs help ensure clinics across the nation adopt these practices as part of achieving optimal postoperative recovery for companion animals.
Companion animal postoperative pain management therapeutics market in United Kingdom is characterized by dynamic adoption of innovative analgesic approaches across a network of private and specialty veterinary practices. A fast product rollout is made possible because of fast supplier interaction and distribution relationships and well-established professional education and dissemination of guidelines create clinician confidence in new treatment options. As greater owner education, telemedicine follow up, and integrated collaborative perioperative care take on greater importance, the market can expand rapidly, and the number of available treatment options will continue to grow.
Companion animal postoperative pain management therapeutics market in France is emerging through strengthened clinical education and growing alignment with broader postoperative care standards. More and more veterinary practices are using both multimodal analgesia as well as locally manufactured products created specifically for their individual needs. Because of this, outreach to veterinarians and clients through alternative methodology, such as the use of collaborative pilot programs, can help create a wider array of post-operative pain management options in veterinary practices in a given area.
As per global companion animal postoperative pain management therapeutics regional outlook, Asia Pacific is strengthening its position through elevated investment in veterinary healthcare infrastructure, growing clinical expertise, and active participation from regional manufacturers adapting therapies to local clinical needs. Key markets are advancing the clinical research and trial activities designed to validate new analgesic methodologies and device adaptations used in companion animal practice. The expanded distribution networks and digital platforms are allowing practitioners improved access to postoperative care solutions; and the emphasis on practitioner education and development of relationships with international partners can accelerate the speed at which knowledge is transferred between practitioners. As government and professional body involvement in particular markets improves, clarity with regard to official regulatory agencies will be facilitated and commercialization will be supported.
Companion animal postoperative pain management therapeutics market in Japan benefits from a sophisticated pharmaceutical sector and strong clinical research capabilities that support development and validation of novel analgesics and delivery systems. Veterinary schools and specialty clinics prefer to use evidence based multimodal methods supported by structured practitioner education and working with the industry. Strong distribution networks and emphasis on providing high-quality veterinary care to a pet's owner can facilitate the adoption of advanced postoperative management techniques by regional veterinary practices.
Companion animal postoperative pain management therapeutics market in South Korea is propelled by technological integration, domestic pharmaceutical development, and growing clinical research in veterinary centers. Veterinary professionals have adopted multimodal analgesia more frequently due to the support provided through distribution networks and educational outreach programs. Working together, manufacturers and clinics have created new ways for clinics to tailor specific products for their local practices. Clinics benefit from the increased expectations of pet owners with more advanced postoperative care due to the use of health monitoring tools.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Focus on Animal Welfare
Advances In Analgesic Formulations
Regulatory Complexity and Variation
Limited Reimbursement and Owner Willingness
Request Free Customization of this report to help us to meet your business objectives.
Competitive landscape in global companion animal postoperative pain management therapeutics market outlook is driven by incumbents launching targeted biologics and by agile vet tech and at-home service startups, forcing differentiation through partnerships, acquisitions, and product launches. Examples include Zoetis rolling out NGF targeting monoclonal antibodies for canine and feline pain and telehealth alliances such as Vetster with PetMed Express, while asset sales and licensing speed portfolio reshaping.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global companion animal postoperative pain management therapeutics industry is propelled by rising pet ownership and higher standards of veterinary care, which drive demand for advanced analgesics and perioperative protocols. Advances in analgesic formulations such as long acting injectables and implants further accelerate clinical adoption and product innovation. Growth is tempered by fragmented regulatory frameworks that complicate approvals and slow market entry. North America remains the dominant region thanks to concentrated veterinary infrastructure and strong R&D, while local anesthetics represent the leading therapeutic segment due to effective nerve blocks and compatibility with multimodal regimens supporting faster recovery and reduced systemic exposure.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 682.5 Million |
| Market size value in 2033 | USD 1285.4 Million |
| Growth Rate | 7.23% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Million |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Companion Animal Postoperative Pain Management Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Companion Animal Postoperative Pain Management Therapeutics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Companion Animal Postoperative Pain Management Therapeutics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Companion Animal Postoperative Pain Management Therapeutics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Companion Animal Postoperative Pain Management Therapeutics Market size was valued at USD 682.5 Million in 2024 and is poised to grow from USD 731.84 Million in 2025 to USD 1285.4 Million by 2033, growing at a CAGR of 7.23% during the forecast period (2026-2033).
Competitive landscape is driven by incumbents launching targeted biologics and by agile vet tech and at-home service startups, forcing differentiation through partnerships, acquisitions, and product launches. Examples include Zoetis rolling out NGF targeting monoclonal antibodies for canine and feline pain and telehealth alliances such as Vetster with PetMed Express, while asset sales and licensing speed portfolio reshaping. 'Zoetis Inc. (Rimadyl, Galliprant)', 'Elanco Animal Health (Onsior)', 'Merck Animal Health', 'Boehringer Ingelheim Animal Health', 'Norbrook Laboratories', 'Dechra Pharmaceuticals', 'Vetoquinol SA', 'Ceva Animal Health', 'Phibro Animal Health', 'Kindred Biosciences', 'Aratana Therapeutics', 'Pacira Biosciences', 'Bimeda Animal Health', 'Huvepharma', 'Virbac SA', 'Associated British Foods', 'Nexcyon Pharmaceuticals', 'VetDC Inc.', 'Torigen Pharmaceuticals', 'Phibro Animal Health'
Improved emphasis on animal welfare within veterinary practice and among pet owners has elevated expectations for postoperative care, directly increasing demand for effective pain management therapeutics. As attitudes shift toward prioritizing comfort and quality of life, clinics adopt standardized analgesia protocols and allocate resources to procure advanced products. Greater owner advocacy and preference for practices that provide comprehensive pain control encourage investment by providers and manufacturers, fostering product development and wider adoption across practices and contributing to overall market expansion.
Multimodal Analgesia Adoption: Veterinary practices are increasingly adopting multimodal analgesia protocols that combine local anesthetics, non-opioid analgesics, and adjunct therapies to optimize postoperative comfort. This qualitative shift reflects growing clinician preference for individualized, procedure-specific pain plans that reduce reliance on single agents and enhance recovery. Cross-disciplinary guideline development and in-clinic training support protocol standardization, encouraging manufacturers to innovate complementary product portfolios. The trend fosters demand for diverse formulations, perioperative services, and integrated care pathways focused on improved animal welfare and clinical outcomes.
Why does North America Dominate the Global Companion Animal Postoperative Pain Management Therapeutics Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
